2.37
14.49%
0.30
プレマーケット:
2.37
前日終値:
$2.07
開ける:
$2.11
24時間の取引高:
5.61M
Relative Volume:
2.44
時価総額:
$517.09M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-8.4643
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
+25.40%
1か月 パフォーマンス:
+29.51%
6か月 パフォーマンス:
+75.56%
1年 パフォーマンス:
+69.29%
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
AKBA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.37 | 517.09M | 194.75M | -51.26M | -23.38M | -0.28 |
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-11-29 | 再開されました | BTIG Research | Buy |
2023-08-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
2023-05-31 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-31 | ダウングレード | Needham | Buy → Hold |
2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-11-14 | 繰り返されました | Needham | Buy |
2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
2019-05-02 | 開始されました | JP Morgan | Overweight |
2019-03-20 | 開始されました | Citigroup | Neutral |
2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
2018-08-10 | 繰り返されました | Needham | Buy |
2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
2017-12-19 | 開始されました | Piper Jaffray | Overweight |
2017-12-07 | 開始されました | BTIG Research | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | Needham | Buy |
2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
2016-11-15 | 開始されました | Aegis Capital | Buy |
2016-09-29 | 開始されました | Brean Capital | Buy |
2016-03-16 | 繰り返されました | Needham | Buy |
2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 10.9%Should You Buy? - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Barclays PLC - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World
What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat
Brokers Set Expectations for AKBA FY2024 Earnings - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat
H.C. Wainwright optimistic on Akebia shares despite risks to commercial opportunity - Investing.com Nigeria
HC Wainwright Reiterates "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia announces ‘multiple positive business updates’ - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Jane Street Group LLC - Defense World
Vafseo tablets start U.S. shipment, Akebia plans Phase 3 trial - Investing.com India
Akebia Therapeutics Announces Multiple Positive Business Updates - citybiz
Akebia's Vafseo Launch Secures Coverage for Nearly All U.S. Dialysis Patients, 99% of Doctors Show Interest - StockTitan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Akebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.com - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Lifted by Barclays PLC - Defense World
Geode Capital Management LLC Has $6.28 Million Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
New Strong Sell Stocks for January 3rd - Yahoo Finance
Akebia Therapeutics Awards Inducement Stock Options to New Employee at $1.90 Per Share - StockTitan
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expands By 21.7% - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - MarketBeat
State Street Corp Purchases 683,287 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by State Street Corp - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Wellington Management Group LLP Takes $534,000 Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years - Yahoo Finance
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - The Eastern Progress Online
Akebia Therapeutics CEO to Present Vafseo Launch Updates at J.P. Morgan Healthcare Conference 2024 - StockTitan
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold Rating - MarketBeat
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - Kilgore News Herald
Akebia Therapeutics to Present at Upcoming Investor Conferences - The Eastern Progress Online
New Strong Sell Stocks for December 5th - Yahoo Finance
Akebia Therapeutics (FRA:AX9) EBITDA : €4.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):